Verma Rajan K, Garg Sanjay
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar, Punjab 160062, India.
J Pharm Biomed Anal. 2005 Jul 15;38(4):633-44. doi: 10.1016/j.jpba.2005.02.026. Epub 2005 Mar 23.
For the development of extended release formulations of glipizide, techniques of thermal and isothermal stress testing (IST) were used to assess the compatibility of glipizide with selected excipients. Initially, differential scanning calorimeter (DSC) was used to evaluate the compatibility. IR spectrum of drug-excipient mixture was also compared with that of pure drug and excipient. Compatibility of excipients defined in the prototype formula was tested using IST. Based on the DSC results alone, magnesium stearate, meglumine, TRIS buffer, and lactose, were found to exhibit interaction with glipizide. Stressed binary mixtures (stored at 50 degrees C for 3 weeks) of glipizide and meglumine showed yellow coloration indicating potential incompatibility. Based on the results of DSC, IR, and/or HPLC, excipients defined in the prototype formula were found to be compatible with glipizide. The optimized formulation developed using the compatible excipients were found to be stable after 3 months of accelerated stability studies (40 degrees C and 75% RH). Overall, compatibility of excipients with glipizide was successfully evaluated using the combination of thermal and IST methods and the formulations developed using the compatible excipients was found to be stable.
为了开发格列吡嗪缓释制剂,采用热应力测试和等温应力测试(IST)技术来评估格列吡嗪与选定辅料的相容性。最初,使用差示扫描量热仪(DSC)评估相容性。还将药物-辅料混合物的红外光谱与纯药物和辅料的红外光谱进行了比较。使用IST测试原型配方中定义的辅料的相容性。仅基于DSC结果,发现硬脂酸镁、葡甲胺、三羟甲基氨基甲烷缓冲液和乳糖与格列吡嗪存在相互作用。格列吡嗪和葡甲胺的应激二元混合物(在50℃下储存3周)出现黄色,表明可能不相容。基于DSC、红外光谱和/或高效液相色谱的结果,发现原型配方中定义的辅料与格列吡嗪相容。使用相容辅料开发的优化制剂在加速稳定性研究(40℃和75%相对湿度)3个月后被发现是稳定的。总体而言,通过热应力测试和IST方法相结合成功评估了辅料与格列吡嗪的相容性,并且发现使用相容辅料开发的制剂是稳定的。